ACB - Aurora Cannabis Inc.
Many marijuana stock investors have a strong positive outlook on the future of the market. If you've been watching the cannabis sector, then you know how volatile and uncertain trading can be. Yet there have been changes that give more upside to what the future of investing can hold. As cannabis is now a class 3 substance federally, more companies are making shifts in their business to get in line with this new legislation.
NASDAQ | TSX: ACB Canadian grant protects Aurora‑developed genetics bred through the company's advanced research and breeding program EDMONTON, AB, May 14, 2026 /PRNewswire/ - Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB), the Canadian-based leading global medical cannabis company, announced today it has been granted Plant Breeders' Rights in Canada for two proprietary cannabis cultivars developed through its world-class breeding program. This certification gives Aurora the exclusive rights to grow, propagate, and sell finished products produced from these varieties.
NASDAQ | TSX: ACB Q1 launches reinforce Aurora's medical‑first strategy, expanding access to high‑quality products across multiple formats Scaled launches across Canada, Europe and Australia support growing demand in regulated international medical markets Continued focus on quality, patient needs and reliable global supply through Aurora's extensive GMP‑certified network EDMONTON, AB, April 28, 2026 /PRNewswire/ - Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB), the Canadian‑based leading global medical cannabis company, is significantly expanding its global medical cannabis portfolio, with new product launches rolling out across Canada, Europe and Australia. The company continues to shape the global cannabis landscape by introducing new products and formats around the world.
Aurora Cannabis Inc. has transformed into a cannabis-focused company with improving international revenue and margins, while spinning off its Bevo division. ACB's balance sheet now shows net cash of C$46.7 million, achieved through equity sales, and enterprise value trades at just 3.8x projected FY27 adjusted EBITDA. I target a 64% upside for ACB to US$5.58 within a year, based on a 6x FY28 adjusted EBITDA multiple, with the stock trading below tangible book value.
Markets don't usually wait for permission — they anticipate it.
NASDAQ | TSX: ACB EDMONTON, AB, April 15, 2026 /PRNewswire/ - Aurora Cannabis Inc. (the "Company" or "Aurora") (NASDAQ: ACB) (TSX: ACB), the Canadian-based leading global medical cannabis company, is pleased to announce it has acquired Safari Flower Company, an established EU GMP certified cannabis cultivator and manufacturer. Aggregate consideration is valued at $26.5 million, subject to customary adjustments, and inclusive of a cash payment of $2 million that is contingent on satisfaction of certain conditions (the "Transaction").
Aurora Cannabis stock has slid 19% YTD as competition and weak consumer cannabis weigh, but strong medical growth and rising margins could shape its next move.
The Canadian cannabis sector continues to evolve in 2026, even as volatility remains elevated. Total Canadian cannabis sales have steadily increased in recent years, showing consistent demand growth. However, pricing pressure and competition continue to challenge margins across the industry. Still, leading companies are adapting through international expansion, scale in retail, and diversification. As a result, investors are closely watching key names for potential upside during sector recoveries.
NASDAQ | TSX: ACB The Globe and Mail's Report on Business Women Lead Here List acknowledges Aurora's commitment to inclusive leadership at the executive level EDMONTON, AB, March 30, 2026 /PRNewswire/ - Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB), the Canadian‑based leading global medical cannabis company, has been named on The Globe and Mail's 2026 Report on Business Women Lead Here list for the second consecutive year. The annual editorial benchmark recognizes publicly traded Canadian companies demonstrating strong executive‑level gender diversity, underscoring Aurora's continued commitment to inclusive leadership.
The cannabis industry has made a tremendous impact on the world. From being once a taboo subject to now a well-respected and much more accepted industry. Even the thought of what may happen to a legal operator could shape the way marijuana stock investors think. At one point during the green rush, the fear of what could happen with no federal reform would shift how the market reacted. But as of 2026, those fears and worries have calmed down a lot.
Marijuana stocks, even with their volatile behavior, still offer diverse investment opportunities. Not every sector or company deals directly with the plant, so investors see this as an opportunity to capitalize. Now, even with that said, MSO and companies that work directly with the plant tend to capture more market share. Also, they are usually the first to see a run in trading when the time comes.
Aurora Cannabis has had a terrible track record in recent years. Even if recent regulatory changes in the U.S. cause a new pot boom, Aurora is unlikely to capitalize on it.
NASDAQ | TSX: ACB Canada's Largest Global Medical Cannabis Company to Discuss Growth Strategy, Key Trends and Market Opportunities EDMONTON, AB, Feb. 17, 2026 /PRNewswire/ - Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB), the Canadian-based leading global medical cannabis company, will participate in TD Cowen's 46th Annual Health Care Conference in Boston, MA. Simona King, Chief Financial Officer at Aurora, will take part in a fireside chat and one-on-one meetings with investors on March 2, 2026.
What is it about the cannabis industry that keeps investors searching for top marijuana stocks to buy? Cannabis started as one of the first waves of peace, love, and rebellion towards many cultural injustices. Today, those same principles are the foundation in spirit. But the evolution of legal cannabis changed the culture forever. In 2026, significant changes have occurred and continue to happen. We have a battle for who will take over, will it be corporate cannabis or will the true cul;tiovaots be able to take back the industry.
NASDAQ | TSX: ACB EDMONTON, AB, Feb. 12, 2026 /PRNewswire/ - Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB), the Canadian-based leading global medical cannabis company, announces the company will ring the Nasdaq closing bell on Wednesday, February 18, 2026, at the Nasdaq MarketSite in New York's Times Square. The ceremony will be led by Aurora's CEO and Executive Chairman, Miguel Martin, alongside a representative of the company's Board of Directors, executive leadership team and other employees.
NASDAQ | TSX: ACB Launch reinforces Aurora's leadership position across key international markets EDMONTON, AB, Feb. 11, 2026 /PRNewswire/ - Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB), the Canadian-based leading global medical cannabis company, is expanding its Aurora® medical portfolio in Australia and New Zealand, delivering patients and prescribers enhanced choice, reliable quality, and easier access to science-backed products. The expansion underscores the company's ongoing dedication to meeting the unique needs of patients and healthcare professionals in the region, reflecting Aurora's strategic focus on long-term global growth.
Aurora Cannabis beat Q3 earnings and sales estimates as medical cannabis momentum drove growth, but persistent consumer weakness pressured the stock outlook.
Aurora Cannabis (NASDAQ: ACB) reported fiscal third-quarter 2026 results that management said reflect its long-running focus on global medical cannabis and a strategy centered on profitability and sustainable growth. The company's fiscal Q3 ended December 31, 2025. Quarterly results highlight international medical growth CEO Miguel Martin said net revenue increased 7% year over year, driven by
Aurora Cannabis Inc. reported in-line financial results for Q3-2026 with increasing revenue and free cash flow. The company will divest its plant propagation segment and focus on international growth with higher profit margins. The company reported lower revenue for consumer cannabis as it prioritizes its cannabis sales for medical and international markets.
Aurora Cannabis Inc. (ACB:CA) Q3 2026 Earnings Call Transcript